On 12/14/23, Pacific Biosciences of Californi (NASDAQ: PACB) stock enjoyed a major increase of 10.5%, closing at $9.79. Moreover, exceptionally high trading volume at 226% of normal accompanied the advance. Relative to the market the stock has been weak over the last nine months but has risen 15.2% during the last week.
Current PriceTarget Research Rating
PACB is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Pacific Biosciences of Californi has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects complementary signals from PTR’s two proprietary measures of a stock’s attractiveness. Pacific Biosciences of Californi has a slightly negative Power Rating of 31 and a very low Appreciation Score of 9, producing the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment